Discovery Workshops Introduce Guatemalans To BioNovelus’ Disruptive Bio-fungicide CR-10
Published: Jul 11, 2017
Phoenix, July 11, 2017 (GLOBE NEWSWIRE) -- / FOR IMMEDIATE RELEASE — BioNovelus (OTC Pink: ONOV) has launched a series of events in Guatemala intended to introduce local producers and growers to disruptive, environmentally-responsible, agricultural solutions. The first presentation was held on July 6 at the Chamber of Commerce in Guatemala City. Additional BioNovelus Discovery Workshops will be held in the main Guatemalan cities from August to October 2017.
BioNovelus presented its first two-hour workshop facilitated by Jean Ekobo, BioNovelus CEO and founder, and agronomic engineer Elmer Nij Reyes from Agrinco, who is in charge of CR-10 agricultural field trials for BioNovelus in Central America.
The great turnout of 34 people for this first workshop included fruit and vegetable producers, coffee growers, large exporters of fruits and vegetables, agro-researchers from a prestigious Guatemalan university, and even representatives from the Ministry of Agriculture.
Mr. Ekobo stated, “This workshop series gives BioNovelus the opportunity to introduce CR-10 face-to-face to the companies that need it most, and to show concrete field trial results. The agricultural producers we met told us their constant challenges and frustration with bacteria and fungi development, especially in greenhouses, and the unfortunate escalated need for them to use three to four toxic chemical agents to try to keep these pathogens under control.”
“These pathogens have a direct influence on the size of yield,” Ekobo continues. “We believe CR-10 can replace the over-usage of chemical agents and therefore help these companies significantly improve their yields and improve their bottom lines while preserving the environment. With the rising global demand for fruits and vegetables, CR-10 comes at the right time.”
In 2015, Guatemala exported $11.8B. The United States is Guatemala’s top export destination ($4.28B)1. Agriculture comprises approximately 75 percent of Guatemala’s export earnings, and accounts for half of the labor force. Close to 40 percent of the agriculture exported is shipped to the United States2.
The Chamber of Commerce of Guatemala City hosted the event and is providing invaluable assistance in the organization and promotion of the workshops. Established in 1894, the Chamber has been an important engine in the development of the Guatemalan commercial and business sector. They are an essential aspect of making speedy and successful connections with Guatemalan companies. BioNovelus is proud to be a member of this organization.
BioNovelus is a biotech company that honors the environment with innovative, cost effective, and disruptive technology-based solutions to crop protection, food security, and health challenges.
This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for the fiscal year 2017 and beyond could differ materially from the Company's current expectations. Forward-looking statements are identified by words such as "anticipates," "projects," "expects," "plans," "intends," "believes," "estimates," "targets," and other similar expressions that indicate trends and future events.
Factors that could cause the Company’s results to differ materially from forward-looking statements regarding the success of the workshops and efficacy of the crop restoration and results of CR-10 include the lack of capital needed to complete testing, the lack of experience with pursuing approval of this product and modifications and receipt of information that may be demanded by the registration of the CR-10 formula and the delays in the various government approval processes unrelated to the product itself. Factors that could cause lower turn-out in the future include the cities we select to have our workshops and the interest in alternatives to existing products, rates of success in CR-10 eradication of fungi and bacteria include the method and timing of applications of CR-10, the impact of the strength of fungi and bacteria contamination, and other environmental conditions resulting in re-infection. Factors that may impact Guatemalan acceptance of our product include the compatibility with other chemical products.
There is no assurance of when registrations in Guatemala will be obtained for CR-10 Biofungicide and various applications as several field trials are still in progress. There is no assurance that the coffee rust application or any other crop protection or post-harvest protection applications will prove commercially viable. There is no assurance that any transaction will be done with Guatemalan distributors.
Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company's products and services, general business and economic conditions beyond the Company's control the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, compatibility with other chemical products, the application of the products, and the Company's success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements because of new information, since these statements may no longer be accurate or timely.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
— 30 —
For more information, http://bionovelus.com
Media contact: Nathalie Ekobo, Marketing & Communications Director BioNovelus, Inc. +1 602-888-3424 ext.1 Info@BioNovelus.com Investor Relations: Anthony J. Parkinson, Chief Information Officer BioNovelus, Inc. +1 602-888-3424 ext.3 Investor.Relations@BioNovelus.com